Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 3/20 | 0.61 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.61 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.61 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.61 |
| ▸ | DTYMK | P23919 | 4/20 | 0.63 |
| ▸ | DPP4 | P27487 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.61 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.61 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.61 |
| ▸ | GAPDH | P04406 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | STAT6 | P42226 | 1/20 | 0.61 |
| ▸ | PI4KA | P42356 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.61 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.61 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL531208 | 0.89 | DTYMK (0.76) | DTYMKADORA3DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL6863617 | 0.89 | DTYMK (0.76) | DTYMKADORA3DPP4MEN1SLC28A1 | |
| Deoxyadenosine SCHEMBL10012867 | 0.88 | DTYMK (0.61) | DTYMKMAPK1SMN1; SMN2 | |
| Adenosine SCHEMBL6247607 | 0.86 | DTYMK (0.58) | DTYMKADORA3DPP4MEN1SLC28A1 | |
| SCHEMBL26646277 | 0.85 | ADORA3 (0.62) | DTYMKADORA3DPP4MEN1SLC28A1 | |
| Vidarabine SCHEMBL6664146 | 0.85 | MAPK1 (0.67) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL9710357 | 0.85 | DTYMK (0.66) | DTYMKADORA3DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL8445960 | 0.84 | ADORA3 (0.68) | DTYMKADORA3DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL8445958 | 0.84 | ADORA3 (0.68) | DTYMKADORA3DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL8846731 | 0.84 | DTYMK (0.69) | DTYMKADORA3DPP4MEN1SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220056441-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | SIRNA THERAPEUTICS INC (US) | 2022-02-24 | — | — | US | disclosed |
| US-10889815-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10662428-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190233821-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | BANK OF AMERICA, N.A. | 2019-08-01 | — | — | US | disclosed |
| US-10351852-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190194658-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190010497-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS INC (US) | 2019-01-10 | — | — | US | disclosed |
| US-20180245083-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS INC (US) | 2018-08-30 | — | — | US | disclosed |
| US-10000754-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-9957517-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| EP-1572067-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005041859-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY. | SIRNA THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005019453-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050032733-A1 | siNA molecule comprising a double-stranded structure that down-regulates expression of Hepatitis B Virus (HBV) , wherein said siNA molecule does not require the presence of nucleotides having a 2'-hydroxy group within the siNA molecule for mediating RNA interference | SIRNA THERAPEUTICS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| US-20050020525-A1 | first nucleotide sequence complementary to a target RNA sequence or a portion thereof, and a second sequence chemically modified so that it can no longer act as a guide sequence for mediating RNA interference, having complementarity to said first sequence; pharmaceutical use such as viricide | SIRNA THERAPEUTICS, INC. | 2005-01-27 | — | — | US | disclosed |
| US-20040249178-A1 | Biological conjugates used for drug delivery; side effect reduction | SIRNA THERAPEUTICS, INC. (US) | 2004-12-09 | — | — | US | disclosed |
| US-20040192626-A1 | siNA molecule comprising a double-stranded structure that down-regulates expression of a target nucleic acid, wherein said siNA molecule does not require a 2'-hydroxyl group containing ribonucleotide; treating viral diseases such as SARS (severe acute respiratory syndrome virus), herpes, hepatitis, HIV | BANK OF AMERICA, N.A. | 2004-09-30 | — | — | US | disclosed |
| US-20040110296-A1 | biological conjugates used for drug delivery; side effect reduction | RIBOZYME PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | disclosed |
| US-20030130186-A1 | Conjugates and compositions for cellular delivery | RIBOZYME PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2002094185-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192626-A1 | siNA molecule comprising a double-stranded structure that down-regulates expression of a target nucleic acid, wherein said siNA molecule does not require a 2'-hydroxyl group containing ribonucleotide; treating viral diseases such as SARS (severe acute respiratory syndrome virus), herpes, hepatitis, HIV | SARS1, EIF2AK2, MAVS | ADORA3 3756/4885ADORA2A 3107/4885ADORA2B 4287/4885 |
| US-10662428-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | AGO2, SNRPE, SRRT | ADORA3 4037/4885ADORA2A 4195/4885ADORA2B 4060/4885 |
| US-20050020525-A1 | first nucleotide sequence complementary to a target RNA sequence or a portion thereof, and a second sequence chemically modified so that it can no longer act as a guide sequence for mediating RNA interference, having complementarity to said first sequence; pharmaceutical use such as viricide | AGO2, SRRT, ADAR | ADORA3 2636/4885ADORA2A 2284/4885ADORA2B 1649/4885 |
| US-20030130186-A1 | Conjugates and compositions for cellular delivery | ALB, FUT5, RNGTT | ADORA3 942/4885ADORA2A 475/4885ADORA2B 1276/4885 |
| US-20190010497-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, SNRPE, SRRT | ADORA3 4037/4885ADORA2A 4195/4885ADORA2B 4060/4885 |
| US-20190194658-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, SNRPE, SRRT | ADORA3 4037/4885ADORA2A 4195/4885ADORA2B 4060/4885 |
| US-20040249178-A1 | Biological conjugates used for drug delivery; side effect reduction | ALB, HEXA, ADAR | ADORA3 890/4885ADORA2A 302/4885ADORA2B 936/4885 |
| US-20040110296-A1 | biological conjugates used for drug delivery; side effect reduction | ALB, HEXA, ADAR | ADORA3 890/4885ADORA2A 302/4885ADORA2B 936/4885 |
| US-10889815-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | AGO2, SNRPE, SRRT | ADORA3 4037/4885ADORA2A 4195/4885ADORA2B 4060/4885 |
| US-20050032733-A1 | siNA molecule comprising a double-stranded structure that down-regulates expression of Hepatitis B Virus (HBV) , wherein said siNA molecule does not require the presence of nucleotides having a 2'-hydroxy group within the siNA molecule for mediating RNA interference | SNRPE, SIN3A, SRRT | ADORA3 3512/4885ADORA2A 2470/4885ADORA2B 3167/4885 |
| US-20220056441-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | AGO2, SNRPE, SRRT | ADORA3 4037/4885ADORA2A 4195/4885ADORA2B 4060/4885 |
| US-20190233821-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, SNRPE, SRRT | ADORA3 4037/4885ADORA2A 4195/4885ADORA2B 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.